[
  {
    "ts": "2026-02-26T21:08:06+00:00",
    "headline": "Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...",
    "summary": "Kymera Therapeutics Inc (KYMR) reports robust financial health and significant progress in clinical trials, setting a strong foundation for future growth.",
    "url": "https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-q4-210806265.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "aa201fb5-9d9d-3a1c-a751-197a0ccb31f7",
      "content": {
        "id": "aa201fb5-9d9d-3a1c-a751-197a0ccb31f7",
        "contentType": "STORY",
        "title": "Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...",
        "description": "",
        "summary": "Kymera Therapeutics Inc (KYMR) reports robust financial health and significant progress in clinical trials, setting a strong foundation for future growth.",
        "pubDate": "2026-02-26T21:08:06Z",
        "displayTime": "2026-02-26T21:08:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-q4-210806265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-q4-210806265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T22:03:35+00:00",
    "headline": "Kymera Therapeutics Q4 Earnings Call Highlights",
    "summary": "Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a “breakout year” driven by clinical progress for its oral STAT6 degrader KT-621, the launch of a new IRF5 degrader program with KT-579 entering the clinic, and strengthened finances",
    "url": "https://www.marketbeat.com/instant-alerts/kymera-therapeutics-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "d3fbbd13-b19c-3a5c-9e2e-c8344bae80fa",
      "content": {
        "id": "d3fbbd13-b19c-3a5c-9e2e-c8344bae80fa",
        "contentType": "STORY",
        "title": "Kymera Therapeutics Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a “breakout year” driven by clinical progress for its oral STAT6 degrader KT-621, the launch of a new IRF5 degrader program with KT-579 entering the clinic, and strengthened finances",
        "pubDate": "2026-02-26T22:03:35Z",
        "displayTime": "2026-02-26T22:03:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2c2c5b64324c5d67fb639832783c9cba",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Kymera Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r6Py7Q6OwG3uh6Rp8.KyiQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2c2c5b64324c5d67fb639832783c9cba.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8O9mkZw2rGbHmbjJerJ5JA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2c2c5b64324c5d67fb639832783c9cba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/kymera-therapeutics-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-q4-earnings-call-220335527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]